Onureg for Acute Myeloid Leukemia (AML)

Eclipse Campaign

Onureg is the first and only continued treatment for AML and launched in the US in September 2020. “The Eclipse” campaign debuted at launch and highlighted this unique treatment for AML by featuring a phenomenon that was pretty unique itself—an eclipse. Digital banners, journal ads, direct mail, and an iVA were just some of the surround sound tactics for HCPs.

Awareness Campaign

In 2021, many physicians had still not heard of Onureg and weren’t clear about which patients were appropriate. This was because the client decided not to prep the AML market for Onureg prior to launch and that it launched amidst a pandemic. The “Onureg Awareness campaign” with its simple yet striking copy and graphics that were featured at conventions, in digital banners, and in print ads, not only helped raise awareness and create buzz in the market post-launch, but also provided clarity about what this once-daily pill could do for AML patients.

“Stranded” Disease Awareness Campaign

oHCM is a rare heart condition with serious consequences, but most people suffer with one misdiagnosis after another, and no effective treatments to help them even if diagnosed. Patients spend years going nowhere…feeling confused, frustrated, lost.

We needed to highlight this issue in a new way and raise awareness and urgency in the medical community. The “Stranded” disease awareness campaign is emblematic of the patient journey and dramatizes the challenges of diagnosing and treating oHCM. Change has been long overdue. A journal ad, banner ads, and an educational web site are just some of the tactics to help build global awareness about the current unmet need of this chronic condition.

The Vines Campaign for Myelofibrosis

“The Vines” was a global unbranded campaign that helped create urgency and awareness about myelofibrosis progression and that worsening symptoms may be creeping up on patients more than HCPs think. Tactical initiatives to help drive the campaign included a journal ad, banner ads, and even a Medscape info site. This pre-launch disease awareness campaign helped set up the need for Inrebic, the first myelofibrosis treatment in a decade, which launched globally in 2021.

Chronic Obstructive Pulmonary Disease (COPD) Franchise

Lonhala Magnair

The Delivery Counts unbranded campaign, the Branded HCP “Nebulization is Going Places” campaign, and the Consumer “Take it With You” campaign helped Lonhala Magnair, the newest nebulizer for COPD, make a successful debut. Promotional materials ranged from traditional tactics to innovative experiences, helping to create excitement and buzz pre and post launch.

Brovana

Brovana has been on the market for a long time for the treatment of COPD, so it was important to continue to stay top of mind for HCPs and patients as a tried-and-trusted brand. The “Second Wind” HCP campaign and “Catch your Second Wind” patient campaign helped to do just that by giving the branded promotional materials a refreshing new look. Institutions and managed markets were also key audiences that we marketed to with a range of clinical initiatives.

Abuse-deterrent Opioid for Pain Management

With more than 2 million Americans abusing and misusing opioids in America today, opioid addiction is a huge problem. “Opioid IQ” was a unique documentary-based platform that featured key insights and tools from renowned pain specialists about how to manage unintentional opioid misuse. This powerful digital experience helped set up the need for abuse-deterrent technology, teasing the upcoming launch of Xtampza, a novel, abuse-deterrent formulation of ER oxycodone for pain management. Xtampza ER launch tactical work for both HCPs and patients featured a range of both print and interactive materials.